Pipeline

February 16, 2020

Company	Drug/Device	Medical Condition	Status
Zhittya Genesis Medicine	FGF-1	Parkinson’s Disease	phase 1 trial initiated in Mexico
SELLAS Life Sciences Group	GPS	malignant pleural mesothelioma	phase 1 trial enrolling first patient
CNS Pharmaceuticals WPD Pharmaceuticals	Berubicin	pediatric brain cancer	phase 1 trial planned in Poland
Antios Therapeutics	ATI-2173	hepatitis B	phase 1a trial enrolling 35 patients
NGM Biopharmaceuticals	NGM120	cancer and cancer anorexia/cachexia syndrome	phase 1a/1b trial initiated
Bold Therapeutics	BOLD-100	gastric, pancreatic, colorectal and bile duct cancers	phase 1b trial initiated in Canada
Inovio Pharmaceuticals	INO-3107	recurrent respiratory papillomatosis	IND for phase 1/2 trial granted by the FDA
Moderna	mRNA-3704	methylmalonic acidemia	phase 1/2 trial enrolling first patient
Alkahest	AKST4290	treatment-naïve neovascular age-related macular degeneration	Phase 2b trial initiated
Rezolute	RZ358	congenital hyperinsulinism	phase 2b trial initiated
Can-Fite BioPharma	Namodenoson	advanced hepatocellular carcinoma	phase 3 trial plan submitted to CHMP
Plasmology4	Plaz4 nonthermal plasma technology	multidrug-refractory bacterial and/or fungal pathogen bioburden in a wound bed	Breakthrough Device designation granted by the FDA
Deciphera Pharmaceuticals	ripretinib	advanced gastrointestinal stromal tumors	priority review granted by the FDA
Bristol-Myers Squibb	liso-cel	relapsed or refractory large B-cell lymphoma	priority review granted by the FDA
Eli Lilly	LOXO-292 (selpercatinib)	non-small cell lung cancer	priority review granted by the FDA
Seattle Genetics	tucatinib	locally advanced unresectable or metastatic HER2-positive breast cancer	priority review granted by the FDA
Astex Pharmaceuticals	C-DEC (cedazuridine and decitabine)	intermediate- and high-risk myelodysplastic syndrome	priority review granted by the FDA
GlaxoSmithKline	belantamab mafodotin	relapsed or refractory multiple myeloma	priority review granted by the FDA
Novartis	capmatinib	non-small cell lung cancer	priority review granted by the FDA
Kite Pharma	KTE-X19	relapsed or refractory mantle cell lymphoma in adults	priority review granted by the FDA